Indeed, HDAC1 inhibition has received attention for therapeutic purposes in solid tumors and hematologic malignancies, even though HDAC1 inhibitors have shown limited responses as single agents in patients with cancer (54, 55). This evidence concerns the gene HDAC1 and cancer.